Susan Siegel - Nevro Corp Independent Director
NVRO Stock | USD 8.81 0.12 1.34% |
Director
Susan Siegel is Independent Director of Nevro Corp since 2020.
Age | 60 |
Tenure | 4 years |
Address | 1800 Bridge Parkway, Redwood City, CA, United States, 94065 |
Phone | 650 251 0005 |
Web | https://nevro.com |
Nevro Corp Management Efficiency
The company has return on total asset (ROA) of (0.1018) % which means that it has lost $0.1018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2849) %, meaning that it created substantial loss on money invested by shareholders. Nevro Corp's management efficiency ratios could be used to measure how well Nevro Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of June 2024, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to drop to -0.19. At this time, Nevro Corp's Non Current Assets Total are very stable compared to the past year. As of the 19th of June 2024, Intangible Assets is likely to grow to about 33 M, while Total Assets are likely to drop about 461.8 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
William Summers | Integer Holdings Corp | 70 | |
Martin Maxwell | Integer Holdings Corp | 62 | |
Jean Hobby | Integer Holdings Corp | 60 | |
Sheila Antrum | Integer Holdings Corp | 62 | |
James Hinrichs | Integer Holdings Corp | 53 | |
Pamela Bailey | Integer Holdings Corp | 72 | |
Brian Concannon | CONMED | 62 | |
Alvin Jeffers | Integer Holdings Corp | 47 | |
Marc Stapley | Glaukos Corp | 50 | |
Aimee Weisner | Glaukos Corp | 51 | |
Mark Foley | Glaukos Corp | 55 | |
Fred Hite | Orthopediatrics Corp | 56 | |
David Bronson | CONMED | 67 | |
Kristina Wright | Paragon 28 | 47 | |
Donald Spence | Integer Holdings Corp | 67 | |
Cheryl Capps | Integer Holdings Corp | 59 | |
Charles Farkas | CONMED | 68 | |
Filippo Passerini | Integer Holdings Corp | 63 | |
Gilbert Kliman | Glaukos Corp | 61 | |
Martha Aronson | CONMED | 53 | |
John Workman | CONMED | 69 |
Management Performance
Return On Equity | -0.28 | ||||
Return On Asset | -0.1 |
Nevro Corp Leadership Team
Elected by the shareholders, the Nevro Corp's board of directors comprises two types of representatives: Nevro Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nevro. The board's role is to monitor Nevro Corp's management team and ensure that shareholders' interests are well served. Nevro Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nevro Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Julie Dewey, Vice President - Investor Relations and Corporate Communications | ||
Elizabeth Weatherman, Independent Director | ||
Brad Vale, Independent Director | ||
Donald Middlebrook, Vice President - Clinical, Regulatory and Quality | ||
Christopher Christoforou, Vice President - Research and Development | ||
Kevin OBoyle, Independent Director | ||
Meredith Vornholt, Vice Marketing | ||
Shawn McCormick, Independent Director | ||
David Caraway, Chief Medical Officer | ||
Christofer Christoforou, Senior Operations | ||
DKeith Grossman, Chairman of the Board, President, Chief Executive Officer | ||
Patrick Schmitz, Vice President - Operations | ||
Richard Carter, Chief Officer | ||
Sridhar Kosaraju, Director | ||
Frank Fischer, Independent Director | ||
Michael DeMane, Lead Independent Director | ||
Kevin Thornal, CEO President | ||
Roderick MacLeod, Chief Financial Officer | ||
Shana MBA, Senior Officer | ||
Michael Carter, Vice President - Global Sales | ||
D Grossman, Chairman of the Board, President, Chief Executive Officer | ||
Susan Siegel, Independent Director | ||
Karen Prange, Independent Director | ||
Kashif Rashid, Chief Compliance Officer, General Counsel, Corporate Secretary | ||
Geeta Kaveti, VP Officer | ||
Niamh Pellegrini, Chief Commercial Officer | ||
Lori Ciano, Chief Human Resource Officer | ||
David MD, Senior Officer | ||
Jon Shear, Senior Development |
Nevro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nevro Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.28 | ||||
Return On Asset | -0.1 | ||||
Profit Margin | (0.19) % | ||||
Operating Margin | (0.32) % | ||||
Current Valuation | 265.86 M | ||||
Shares Outstanding | 36.73 M | ||||
Shares Owned By Insiders | 3.80 % | ||||
Shares Owned By Institutions | 96.20 % | ||||
Number Of Shares Shorted | 3.68 M | ||||
Price To Earning | (63.38) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Nevro Stock
When determining whether Nevro Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nevro Corp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nevro Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nevro Corp Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nevro Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Nevro Stock, please use our How to Invest in Nevro Corp guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nevro Corp. If investors know Nevro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nevro Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Revenue Per Share 11.898 | Quarterly Revenue Growth 0.058 | Return On Assets (0.10) | Return On Equity (0.28) |
The market value of Nevro Corp is measured differently than its book value, which is the value of Nevro that is recorded on the company's balance sheet. Investors also form their own opinion of Nevro Corp's value that differs from its market value or its book value, called intrinsic value, which is Nevro Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nevro Corp's market value can be influenced by many factors that don't directly affect Nevro Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nevro Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nevro Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nevro Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.